Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 8/20 | 0.56 |
| ▸ | CA1 | P00915 | 8/20 | 0.56 |
| ▸ | CA2 | P00918 | 8/20 | 0.56 |
| ▸ | CA9 | Q16790 | 8/20 | 0.56 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.52 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.49 |
| ▸ | RNF168 | Q8IYW5 | 1/20 | 0.49 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.47 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025884 | 0.93 | CA12 (0.58) | CA12CA1CA2CA9ITGB1 | |
| SCHEMBL10025883 | 0.89 | CA12 (0.59) | CA12CA1CA2CA9ITGB1 | |
| SCHEMBL11896715 | 0.83 | CA12 (0.59) | CA12CA1CA2CA9ITGB1 | |
| SCHEMBL14308477 | 0.80 | CA12 (0.72) | CA12CA1CA2CA9ITGB1 | |
| SCHEMBL17875149 | 0.80 | PSMD11 (0.34) | CA12CA1CA2CA9ITGB1 | |
| SCHEMBL2054841 | 0.79 | CA12 (0.51) | CA12CA1CA2CA9ITGB1 | |
| SCHEMBL6372736 | 0.78 | CA12 (0.79) | CA12CA1CA2CA9ITGB1 | |
| SCHEMBL11896832 | 0.76 | CA12 (0.55) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL18779801 | 0.76 | TDP1 (0.78) | CA12CA1CA2CA9ITGB1 | |
| SCHEMBL3297576 | 0.75 | F2 (0.57) | CA12CA1CA2CA9ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178314-B2 | Pyrimidines reacting with O6-alkylguanine-DNA alkyltransferase fusion protein and method for detecting protein | COVALYS BIOSCIENCES AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8178314-B2 | Pyrimidines reacting with O6-alkylguanine-DNA alkyltransferase fusion protein and method for detecting protein | COVALYS BIOSCIENCES AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-20090186373-A1 | Pyrimidines reacting with O6-Alkylguanine-DNA alkyltransferase | COVALYS BIOSCIENCES AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186373-A1 | Pyrimidines reacting with O6-Alkylguanine-DNA alkyltransferase | COVALYS BIOSCIENCES AG (CH) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186373-A1 | Pyrimidines reacting with O6-Alkylguanine-DNA alkyltransferase | HPRT1, UNG, DPYD | CA12 4280/4885CA1 4529/4885CA2 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.